CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"North Immunology goes public via reverse merger as eczema drug heads toward clinic","$":{"href":"/biotech/north-immunology-goes-public-reverse-merger-eczema-drug-heads-toward-clinic","hreflang":"en"}}]}

IPO/OfferingPositive
AI Analysis

Summary

North Immunology is going public via reverse merger to fund development of its atopic dermatitis drug heading toward clinical trials.

Outcome Details

reverse merger

Importance:6/10
Sentiment:
0.50
IPOreverse mergeratopic dermatitisclinical development

Read the original article

Published by FierceBiotech on September 17, 2026 7:43 AM

Read Original